SimCorp ernennt Peter Sanderson zum Chief Executive Officer
Sanderson weist eine Erfolgsbilanz beim Vorantreiben von Wachstum vor und verfügt über umfassende Branchenkenntnisse Sanderson war in wichtigen Führungspositionen bei GAM Investments und BlackRock Investment Management tätig KOPENHAGEN, Dänemark und LONDON und NEW YORK, 4. August 2025 /PRNewswire/ — SimCorp, ein weltweit führender Anbieter von Finanztechnologie und eine Tochtergesellschaft der Deutsche Börse AG, gab heute bekannt, […]
SimCorp nomme Peter Sanderson au poste de directeur général
M. Sanderson a fait ses preuves en matière de génération de croissance et possède une connaissance approfondie du secteur M. Sanderson a occupé des postes de direction clés chez GAM Investments et BlackRock Investment Management COPENHAGUE, Danemark, LONDRES et NEW YORK, 4 août 2025 /PRNewswire/ — SimCorp, un leader mondial de la technologie financière et une filiale de […]
Vantage bekroond met de titel “Best Regulated Trading Platform” tijdens de Wealth Expo Ecuador 2025
PORT VILA, Vanuatu, 4 augustus 2025 /PRNewswire/ — Vantage Markets maakte met trots een succesvol debuut tijdens Wealth Expo Ecuador 2025, dat op 19 juli doorging in het Quorum Convention Center in Quito. Als hoofdsponsor van het evenement demonstreerde Vantage haar aanwezigheid tijdens het evenement en werd bekroond met de award “Best Regulated Trading Platform” door […]
SimCorp nombra a Peter Sanderson como consejero delegado
Sanderson cuenta con una trayectoria demostrada impulsando el crecimiento y un profundo conocimiento del sector. Sanderson ha ocupado puestos de liderazgo clave en GAM Investments y BlackRock Investment Management. COPENHAGUE, Dinamarca y LONDRES y NUEVA YORK, 4 de agosto de 2025 /PRNewswire/ — SimCorp, líder mundial en tecnología financiera y filial de Deutsche Börse AG, […]
IRBT Investors Have Opportunity to Lead iRobot Corporation Securities Fraud Lawsuit
NEW YORK, Aug. 4, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iRobot Corporation (NASDAQ: IRBT) between January 29, 2024 and March 11, 2025, both dates inclusive (the “Class Period”), of the important September 5, 2025 lead plaintiff deadline. So What: If you purchased iRobot […]
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm
NEW YORK, Aug. 4, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has […]
Michael Fuller Joins King Street’s European Real Estate Team as Managing Director
LONDON, Aug. 4, 2025 /PRNewswire/ — King Street Capital Management (“King Street” or “the Firm”), a leading global alternative investment firm, today announced that Michael Fuller has joined the firm as a Managing Director on its European Real Estate team. Based in London, Mr. Fuller will report to Paul Brennan, Partner and Co-Head of Real Estate […]
Cybercriminals Abandon Tech Tricks for Personalized Deception Tactics, VIPRE’s Q2 2025 Email Threat Report Reveals
Customized phishing kits propagate; Scandinavia is a BEC target; Lumma Stealer is the top malware family; and favored persuasion and conversion tactics are revealed LONDON, Aug. 4, 2025 /PRNewswire/ — VIPRE Security Group, a global leader and award-winning cybersecurity, privacy, and data protection company, has released its email threat landscape report for Q2 2025. Through an examination […]
Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease
BEIJING, Aug. 3, 2025 /PRNewswire/ — Raytone Biotech, a clinical-stage biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacrimal canaliculus plug for the treatment of dry eye disease (DED). The milestone was achieved at […]
Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer
TAIPEI, Aug. 4, 2025 /PRNewswire/ — Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1/2 clinical trial in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC). This open-label, multi-center international study […]